Melanoma Research Victoria

Source: The ASCO Post, April 2019 In the phase IIIb/IV CheckMate 511 study reported by Lebbé et al in the Journal of Clinical Oncology, a regimen of nivolumab at 3 mg/kg plus ipilimumab at 1 mg/kg (NIVO3+IPI1) was found to significantly reduce the incidence of treatment-related grade 3 to 5 adverse events compared with nivolumab at 1 […]

Read the full story

Source: Pharma Times, April 2019 New therapeutic approaches for treating patients with earlier-stage melanoma who face a higher risk of recurrence are among the features of recently updated consensus guidelines from the Society for Immunotherapy of Cancer (SITC).1The guidelines take stock of the extensive changes that have occurred in the field in less than a […]

Read the full story

Source: Cancer Therapy Advisor, April 2019 A 3-center studyusing viral therapy talimogene laherparepvec (TVEC; Imlygic) in advanced melanoma has reported some of the best patient response rates since the drug was approved by the US Food and Drug Administration (FDA) in 2015.1 The research involved patients from Emory University, Atlanta, Georgia; the Moffitt Cancer Center, […]

Read the full story

Source: Healio, March 2019 ATLANTA — The combination of the histone deacetylase inhibitor entinostat and the anti-PD-1 inhibitor pembrolizumab induced clinical responses and appeared well-tolerated among patients with melanoma that progressed on prior anti-PD-1 treatment, according to results from the single-arm ENCORE 601 phase 1b/phase 2 clinical trial presented at American Association of Cancer Research Annual Meeting. […]

Read the full story